Micro Aftermath Archived

BHVN मोटापा अध्ययन में नामांकन पूरा करता है

गतिविधि घट रही है — नैरेटिव प्रासंगिकता खो रहा है।

स्कोर
0.3
गति
▲ 0.0
लेख
5
स्रोत
2

शीर्ष मूवर्स

टिकरसेक्टरपरिवर्तन
BHVN
Healthcare+97.3%

भावना समयरेखा

सेक्टर प्रदर्शन

स्टॉक प्रदर्शन

घटना समयरेखा

अप्र 22, 2026
Moderate Buy Rating Seen For Biohaven Ltd. (BHVN) Neutral
अप्र 21, 2026
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating Bullish
अप्र 13, 2026
Why Biohaven Stock Crushed it on Monday Bullish
अप्र 01, 2026
Biohaven (BHVN) Fuels Confidence With Encouraging Azetukalner Data Bullish
मा 28, 2026
Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa Neutral

संबंधित लेख

Why Biohaven Stock Crushed it on Monday

Nasdaq · अप्र 14, 2026
Mixed
🤖

AI अवलोकन

What happened: Biohaven Pharmaceuticals (BHVN) completed enrollment in a Phase 2 obesity study for its drug candidate, taldefgrobep alfa, on March 19, 2026. This follows analyst Ken Cacciatore from TD Cowen increasing his price target on BHVN from $15 to $30 on March 11, citing encouraging data from the company's Azetukalner program.

Market impact: The biopharmaceutical sector, particularly small-cap stocks, is affected. BHVN's stock surged on the news, driven by increased investor confidence in the company's pipeline. Hedge funds have also shown interest, with BHVN appearing in the top 7 small-cap healthcare stocks to buy.

What to watch next: Upcoming catalysts include the release of interim data from the taldefgrobep alfa obesity study in Q4 2026, regulatory decisions on Azetukalner, and BHVN's Q2 2026 earnings report, scheduled for mid-May.
एआई अवलोकन के अनुसार अप्र 15, 2026

समयरेखा

पहली बार देखामा 28, 2026
अंतिम अपडेटमा 28, 2026